At the 6th China International Import Expo (CIIE) in Shanghai, pharmaceutical giant Pfizer presented its latest offerings, with its Oncology Day event drawing attention to new therapeutic options. The event served as a platform for discussion of innovative oncology medicines, improving standardized diagnosis and treatment in oncology, as well as all-round patient care and services.

This photo shows the Pfizer booth at the 6th China International Import Expo (CIIE) in east China's Shanghai, Nov. 8, 2023. [Photo/Xinhua]

This year, highlighting significant developments, Pfizer unveiled a pioneering PARP inhibitor for the treatment of metastatic castration-resistant prostate cancer (mCRPC), and a bispecific antibody drug for the treatment of multiple myeloma.

Talazoparib is the world's first and only PARP inhibitor approved by the U.S. Food and Drug Administration for use in combination with enzalutamide for the treatment of metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair gene mutation (HRRm).

Under China's policy encouraging early adoption of innovative therapies, talazoparib was admitted to the Hainan Boao Lecheng International Medical Tourism Pilot Zone, helping more mCRPC patients receive innovative treatment in line with international standards.

Elranatamab is a bispecific antibody targeting BCMA and CD3, used to treat adult patients with relapsed or refractory multiple myeloma (RRMM) who have previously received at least four lines of treatment. Multiple myeloma (MM) is the second most common malignant tumor of the hematological system, with fewer than half of patients surviving more than five years, facing the clinical dilemma of difficulty in treatment and susceptibility to relapse. China has joined the simultaneous global development of multiple clinical trials of elranatamab, which is expected to benefit more patients earlier.

During this year's CIIE, Pfizer also demonstrated its progress in the standardized diagnosis and treatment of lung cancer and breast cancer, as well as the Pfizer Oncology One-Stop Service Solution for cancer patients, aiming to simplify and improve the treatment process.

Linda Wang, general manager of Pfizer China's Oncology Business Unit, speaks at the Oncology Day event during the 6th China International Import Expo (CIIE) in Shanghai, Nov. 8, 2023. [Photo provided to China.org.cn]

Linda Wang, general manager of Pfizer China's Oncology Business Unit, emphasized the company's future direction, saying, "Pfizer will continue to join hands with industry partners," in order to embody the concept of "bringing breakthroughs that change patients' lives." She highlighted their commitment to enhancing the accessibility and affordability of innovative medicines and improving patient treatment experiences, all contributing to the "Healthy China 2030" goals. 

Related

Go to Forum >>0 Comment(s)